Advanced

Increased alveolar nitric oxide in early systemic sclerosis.

Wuttge, Dirk LU ; Bozovic, Gracijela LU ; Hesselstrand, Roger LU ; Aronsson, David LU ; Bjermer, Leif LU ; Scheja, Agneta LU and Tufvesson, Ellen LU (2010) In Clinical and Experimental Rheumatology 28(5 Suppl 62). p.5-9
Abstract
OBJECTIVES: Assessment of inflammatory activity in interstitial lung disease of systemic sclerosis (SSc) is difficult. Nitric oxide (NO) has gained attention in the pathogenesis of SSc. The aim of the study was to investigate alveolar NO concentration (CA(NO)) in SSc patients with short disease duration and to relate CA(NO) to radiologic findings. METHODS: In a prospective study, 34 consecutive patients with disease duration of less than 2 years from onset of first non-Raynaud symptom and 26 healthy controls were enrolled. Exhaled NO was measured and CA(NO) was calculated. CA(NO) levels were related to the radiologic extent of pulmonary fibrosis measured as the extent of traction bronchiectasis within areas of ground glass opacities and... (More)
OBJECTIVES: Assessment of inflammatory activity in interstitial lung disease of systemic sclerosis (SSc) is difficult. Nitric oxide (NO) has gained attention in the pathogenesis of SSc. The aim of the study was to investigate alveolar NO concentration (CA(NO)) in SSc patients with short disease duration and to relate CA(NO) to radiologic findings. METHODS: In a prospective study, 34 consecutive patients with disease duration of less than 2 years from onset of first non-Raynaud symptom and 26 healthy controls were enrolled. Exhaled NO was measured and CA(NO) was calculated. CA(NO) levels were related to the radiologic extent of pulmonary fibrosis measured as the extent of traction bronchiectasis within areas of ground glass opacities and reticulations. RESULTS: CA(NO) levels were increased in patients with early SSc compared to healthy controls (3.52 (2.94-4.09) versus 2.08 (1.6-2.6); p<0.001). Both SSc patients with SSc-ILD (3.56 (3.04-4.73), p<0.001) and SSc patients without SSc-ILD (2.98 (2.68-3.98), p<0.01) had higher CA(NO) levels compared with healthy controls (2.08 (1.6-2.6)). CA(NO) levels did not differ between SSc patients without SSc-ILD and SSc patients with SSC-ILD. CA(NO) levels did not correlate to the extent of pulmonary fibrosis but were associated with the extent of ground glass opacities (rs=0.37, p<0.05) and reticulations (rs=0.37, p<0.05) on HRCT. CA(NO) levels were not correlated to lung function tests. CONCLUSIONS: In patients with early SSc, alveolar NO is increased and may precede radiological changes of SSc-ILD. CA(NO) may therefore be a marker of early lung involvement. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical and Experimental Rheumatology
volume
28
issue
5 Suppl 62
pages
5 - 9
publisher
Pacini
external identifiers
  • wos:000284028600002
  • pmid:21050538
  • scopus:78650567530
ISSN
1593-098X
language
English
LU publication?
yes
id
dba97302-c104-42b0-ba84-a19507bfd67b (old id 1731792)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21050538?dopt=Abstract
date added to LUP
2010-12-01 13:05:50
date last changed
2018-06-03 04:30:50
@article{dba97302-c104-42b0-ba84-a19507bfd67b,
  abstract     = {OBJECTIVES: Assessment of inflammatory activity in interstitial lung disease of systemic sclerosis (SSc) is difficult. Nitric oxide (NO) has gained attention in the pathogenesis of SSc. The aim of the study was to investigate alveolar NO concentration (CA(NO)) in SSc patients with short disease duration and to relate CA(NO) to radiologic findings. METHODS: In a prospective study, 34 consecutive patients with disease duration of less than 2 years from onset of first non-Raynaud symptom and 26 healthy controls were enrolled. Exhaled NO was measured and CA(NO) was calculated. CA(NO) levels were related to the radiologic extent of pulmonary fibrosis measured as the extent of traction bronchiectasis within areas of ground glass opacities and reticulations. RESULTS: CA(NO) levels were increased in patients with early SSc compared to healthy controls (3.52 (2.94-4.09) versus 2.08 (1.6-2.6); p&lt;0.001). Both SSc patients with SSc-ILD (3.56 (3.04-4.73), p&lt;0.001) and SSc patients without SSc-ILD (2.98 (2.68-3.98), p&lt;0.01) had higher CA(NO) levels compared with healthy controls (2.08 (1.6-2.6)). CA(NO) levels did not differ between SSc patients without SSc-ILD and SSc patients with SSC-ILD. CA(NO) levels did not correlate to the extent of pulmonary fibrosis but were associated with the extent of ground glass opacities (rs=0.37, p&lt;0.05) and reticulations (rs=0.37, p&lt;0.05) on HRCT. CA(NO) levels were not correlated to lung function tests. CONCLUSIONS: In patients with early SSc, alveolar NO is increased and may precede radiological changes of SSc-ILD. CA(NO) may therefore be a marker of early lung involvement.},
  author       = {Wuttge, Dirk and Bozovic, Gracijela and Hesselstrand, Roger and Aronsson, David and Bjermer, Leif and Scheja, Agneta and Tufvesson, Ellen},
  issn         = {1593-098X},
  language     = {eng},
  number       = {5 Suppl 62},
  pages        = {5--9},
  publisher    = {Pacini},
  series       = {Clinical and Experimental Rheumatology},
  title        = {Increased alveolar nitric oxide in early systemic sclerosis.},
  volume       = {28},
  year         = {2010},
}